Can it be a powerful ark of the future because of the initial evidence that supports the long-term health benefits of GLP-1-based drugs to reduce the risks of cancer and dementia?
For future generations, it is very reasonable to say that the most important 50th birthday gift will be an Oz pick prescription of GP designed to slow down aging and extend the health of the years.
This is a provocative proposal from the associate professor of Albert Einstein College of Medicine, one of the world’s leading old research hubs. He says evidence As a powerful anti-aging tool in the future, we gradually point out the role of drugs that mimic intestinal hormones such as GLP-1.
“The concept of delaying or preventing healthy mid -ripper’s aging -related reductions by using intestinal hormones is biologically healthy and more and more realized.” I paper.
His opinion has reached the second half of another amazing evidence that supports the long-term health benefits of GLP-1-based drugs such as Ozempic, Wegovy and Mounjaro.
Earlier this month, in parliamentary parliamentary European obesity, experts published a study that published a study that the drug caused a strong anticancer effect. Others have reduced the death of GLP-1 drugs in half. It can prevent the recurrence of atrial fibrillationChronic state, which is characterized by irregular heartbeat, one of the general causes of stroke. In other places, scientists have found that it may be slow to take weight loss drugs. Cognitive decline And lines Mental health Like anxiety.
Such discovery is in question, can you someday take this medicine by slim people to help you live a longer life without a disease?
When the GLP-1 drug first appeared in the field five years ago, it was thought that the ability to increase the appetite would reduce chronic diseases, causing a dramatic decrease in weight and body fat over the years or years. As obesity is the root cause of other chronic diseases, it has been assumed for a long time as the main reason for the effects of various conditions, ranging from severe fatty liver disease to sleep disorders.
However, as Santulli explained, the excitement of excitement comes from the new data collected in clinical trials and laboratory, and shows that positive effects on the body have a positive effect that exceeds weight loss. In fact, he is becoming more and more clear that GLP-1 drugs can control some of the most fundamental biological processes behind aging.
First of all, they improve the ability to remove cancer cells before raising the immune system and developing tumors, and weaken the chronic inflammation that progresses as you age. This is thought to be one of the reasons why the pain decreases and mobility is improved while patients with osteoarthritis in the knee joints are taking drugs.
Santulli said, “This is a new concept.” Observation suggests much more GLP-1 than saturous hormones, which reduces systemic inflammation and modifies innate immunity. GLP-1 also prevents the age-related stiffness of blood vessels, changes energy metabolism, and can also adjust a system that prevents age-related damage.
Link to intestinal hormone and longevity
Jens Juul Holst is one of the small male and female scientists who played an important role in the discovery of GLP-1 and the many roles of the body in the 1980s. HOLST not only conducted basic science, but also helped Novo Nordisk, a Danish pharmaceutical company (ultimately developed Wegovy and Ozempic to warn the effects of blood sugar and appetite, but 40 years ago, he had little thought that his work would ultimately lead to the fastest drug.
In the early days he knew it seemed to be associated with those who had undergone obesity between this bowl hormone and longevity. It has been consistently longer Than people who receive standard obesity.
Holst, an active researcher at the 79 -year -old University of Copenhagen, said, “Holst, a 79 -year -old researcher at the age of hundreds of thousands of individuals who received the above -hand operation, said. I paper. “The data is very consistent. How does this surgery work? They release another chapter hormone called GLP-1 and PYY.”
With this in mind, HOLST is especially interested in the new ideas proposed by Santulli. GLP-1 drugs will help you aged 65 or older, especially your health. Perhaps it can be emphasized by blood tests. This is a weak level of inflammatory protein or falls, which is more vulnerable to fall and more vulnerable to falls.
Of course, there is a risk of giving the elderly to suppress appetite. This age group is vulnerable to a state that is known as an ‘anorexia of aging’, which has already decreased appetite and malnutrition. But Santulli thinks it can be solved through two means. Add more appetite for them and treat these people with low or ‘microdo’ of GLP-1.
“Appetite will be a real interest, but potential solutions can still include low-dose GLP-1 that acts on aging paths without providing the benefits of anti-inflammatory drugs and affecting the vineyard center of the brain.” “We have built known appetite stabilizer drugs such as Anamorelin. Also, muscle overeating can monitor the intake in advance so that it does not change.”
It is a bold plan, and if such a study is trying to show positive results, Santulli thinks that it is possible to enjoy a wider health benefits by enabling more obese individuals in their 40s, 50s and 60s by packing the possibility of opening a way for a wide range of approach to GLP-1.
But in order to be a reality, there are still some challenges to overcome.
Long longer life -but less enjoyable life?
David D ‘Alessio, a professor of endocrine and ambassadors at Duke University, is one of the costs of Duke University, the largest barrier to the concept of providing GLP-1 drugs to Midlifers. “In the United States, it costs $ 1000-1500 a month,” he says. “When multiplied by the number of people who don’t want to grow old in that time, you get something coming to infinity.”
Two things can be changed. The first is the steady expiration of the patent, giving pharmaceutical companies a monopoly right about how the price of these drugs is set. Last year, the patent of Novo Nordisk, which was sold by SAXENDA, an initial GLP-1 drug of Novo Nordisk, expired, and between 2026 and 2033, the company’s various patents for Ozempic and Wegovy and American Pharma Giant Eli Lilly, which creates MOUNJARO. The various patents of the company will be over.
This allows competitors to reduce costs by creating a general form of this drug. D ‘Alessio said, “Patent expiration is important for the potential of this drug to actually have a wide range of effects.
Second, GLP-1 drugs are currently administered as injections, while manufacturing costs are more expensive and less pleasant to users, but the company has begun to break the mystery producing pills. Holst said, “This was very difficult, but ELI lilly produced Orforglipron.” It is much easier to produce and eventually cheaper. “
In addition, when taking Wegovy or Mounjaro for obesity, it seems to be very effective in fighting the loss of pleasure, with the acute nausea and gastrointestinal problems that certain numbers experience, and the addictive from alcohol to opioid.
Holst says that this raises an important philosophical problem. Would people really want people to live longer if they take drugs that limit their lives?
“The pharmaceutical company doesn’t talk much about this,” he says. “But the drug affects this compensation is very well established, especially that it is not fun to enjoy food, alcohol, and all the pleasure of life. Therefore, you can just eat GLP-1 drugs to everyone.”
But as with the proposed research of Santulli’s elderly, Microdosing can provide an answer.
Is Microdosing using the answer?
Given the high cost of GLP-1 drugs, more reports in the United States will appear and those who buy the vials of WEGOVY and MOUNJARO are deliberately administered to them with customized doses that are much smaller than recommended.
In addition to preserving supply and cost savings, this kind of microding has been found to be an effective way to avoid continuous side effects, especially for those who have already reached the desired weight goal and simply trying to maintain weight for a longer time.
HOLST is interested in this development, and now Microding says that it should be more widely studied in clinical trials. It can also show a path to expand the access to GLP-1 without excessive dampness of the brain.
At this time, I don’t think there’s enough evidence that these drugs are used as a preventive tool for those who are already healthy, but I think it will increase for young people, not obesity. However, they have a kind of metabolic syndrome to manage automatic immune diseases such as type 1 diabetes, to pressure blood pressure or to increase exemplary population resistance.
“In many countries, there is one quarter of the adult population with metabolic syndrome, which greatly increases the risk of cardiovascular disease and early death.” “This is a lot of people, and we know that GLP-1 drugs can do something about it. So I think the government has a fantastic opportunity and almost obligations to reduce risk using these drugs.”
In the future, HOLST can eventually reach a situation in which people can go to GP and get blood tests, and if the metabolic health is not good, it can help to normalize these symptoms before developing more serious.
“Take blood samples and see blood lipids, cholesterol levels, blood pressure, etc.,” he says. “It will be like statins.”
